secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXAGEN INC. (XGN)
CIK:        0001274737
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0001274737-22-000051
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Exagen Q2 revenue $9.0M, net loss $13.3M; cuts 2022 guidance to $35-40M
-----------------------------------------------------------------------

- AVISE CTD volume hit record 34,919 tests, up 5% YoY and 13% sequentially.
- Revenue fell to $9.0M from $12.8M YoY; gross margin dropped to 32.2% from 57.3%.
- Net loss widened to $13.3M from $6.4M loss in Q2 2021.
- 2022 revenue guidance revised to $35-40M, citing Medicare reimbursement uncertainty.
- Record 2,273 ordering providers and 797 adopters; ~100M in-network lives under contract.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1274737/000127473722000051/0001274737-22-000051-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1274737/000127473722000051/exdx-20220804.htm
  HTML page:      https://secwatch.observer/filing/0001274737-22-000051

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer